[1]
Georgakopoulos CD, Plotas P, Angelakis A, Kagkelaris K, Tzouvara E, Makri OE. Dexamethasone implant for immunogammopathy maculopathy associated with IgA multiple myeloma. Therapeutic advances in ophthalmology. 2019 Jan-Dec:11():2515841418820441. doi: 10.1177/2515841418820441. Epub 2019 Jan 8
[PubMed PMID: 30671569]
Level 3 (low-level) evidence
[2]
Abrams RMC, Elder GA. Safety of Therapeutic Plasma Exchange for the Treatment of Guillain-Barré Syndrome in Polycythemia Vera. The neurologist. 2018 Nov:23(6):185-187. doi: 10.1097/NRL.0000000000000197. Epub
[PubMed PMID: 30379740]
[3]
Daniel R, Chan RY. Hyperviscosity syndrome in splenic marginal zone lymphoma. Blood. 2018 Oct 11:132(15):1627. doi: 10.1182/blood-2018-07-863787. Epub
[PubMed PMID: 30309878]
[4]
Espinosa-Barberi G, Galván González FJ, Miranda Fernández S, Viera Peláez D, Medina Rivero F, Marrero Saavedra D. Vasoproliferative retinopathy secondary to Waldenström's disease. Archivos de la Sociedad Espanola de Oftalmologia. 2019 Feb:94(2):85-89. doi: 10.1016/j.oftal.2018.09.006. Epub 2018 Oct 11
[PubMed PMID: 30318175]
[5]
Higdon ML, Atkinson CJ, Lawrence KV. Oncologic Emergencies: Recognition and Initial Management. American family physician. 2018 Jun 1:97(11):741-748
[PubMed PMID: 30215936]
[6]
Tedeschi A, Conticello C, Rizzi R, Benevolo G, Laurenti L, Petrucci MT, Zaja F, Varettoni M. Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia. Hematological oncology. 2019 Apr:37(2):117-128. doi: 10.1002/hon.2539. Epub 2018 Sep 7
[PubMed PMID: 30192023]
[7]
Castillo JJ, Treon SP. Initial Evaluation of the Patient with Waldenström Macroglobulinemia. Hematology/oncology clinics of North America. 2018 Oct:32(5):811-820. doi: 10.1016/j.hoc.2018.05.008. Epub 2018 Jul 23
[PubMed PMID: 30190019]
[8]
Miyamoto Y, Hamasaki Y, Matsumoto A, Doi K, Noiri E, Nangaku M. Prediction of immunoglobulin M reduction via therapeutic dose of simple plasma exchange and double filtration plasmapheresis using membrane separation in patients with hyperviscosity syndrome caused by Waldenstrom macroglobulinemia. Journal of clinical apheresis. 2018 Oct:33(5):611-615. doi: 10.1002/jca.21655. Epub 2018 Sep 6
[PubMed PMID: 30188580]
[9]
Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, Bento C, McMullin MF, Percy M, Cario H. Primary Familial and Congenital Polycythemia. GeneReviews(®). 1993:():
[PubMed PMID: 27831681]
[10]
Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA, Leleu X, McMaster M, Merlini G, Minnema MC, Morra E, Owen RG, Poulain S, Stone MJ, Tam C, Varettoni M, Dimopoulos MA, Treon SP, Kastritis E. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. British journal of haematology. 2016 Oct:175(1):77-86. doi: 10.1111/bjh.14196. Epub 2016 Jul 5
[PubMed PMID: 27378193]
[11]
Jeevasankar M, Agarwal R, Chawla D, Paul VK, Deorari AK. Polycythemia in the newborn. Indian journal of pediatrics. 2008 Jan:75(1):68-72
[PubMed PMID: 18245939]
[12]
Ballestri M, Ferrari F, Magistroni R, Mariano M, Ceccherelli GB, Milanti G, De Palma M, Albertazzi A. Plasma exchange in acute and chronic hyperviscosity syndrome: a rheological approach and guidelines study. Annali dell'Istituto superiore di sanita. 2007:43(2):171-5
[PubMed PMID: 17634666]
[13]
Mullen EC, Wang M. Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia. Clinical journal of oncology nursing. 2007 Feb:11(1):87-95
[PubMed PMID: 17441400]
[14]
Zarkovic M, Kwaan HC. Correction of hyperviscosity by apheresis. Seminars in thrombosis and hemostasis. 2003 Oct:29(5):535-42
[PubMed PMID: 14631553]
[15]
Chen YY, Yen YF, Lin JX, Feng SC, Wei LC, Lai YJ, Shen YC. Risk of Ischemic Stroke, Hemorrhagic Stroke, and All-Cause Mortality in Retinal Vein Occlusion: A Nationwide Population-Based Cohort Study. Journal of ophthalmology. 2018:2018():8629429. doi: 10.1155/2018/8629429. Epub 2018 Sep 9
[PubMed PMID: 30271630]
[16]
Haris A, Arányi J, Braunitzer H, Kálmán E, Merán Z, Soltész M, Polner K. [Role of plasmapheresis in immunological kidney diseases. Experience from 1050 completed plasmapheresis treatment sessions]. Orvosi hetilap. 2011 Jul 10:152(28):1110-9. doi: 10.1556/OH.2011.29155. Epub
[PubMed PMID: 21712172]